Sequential gene expression of P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP) and lung resistance protein:: functional activity of P-gp and MRP present in the doxorubicin-resistant human K562 cell lines

被引:28
作者
Grandjean, F
Brémaud, L
Verdier, M
Robert, J
Ratinaud, MH
机构
[1] Fac Med Limoges, Grp Physiol Mol Mitochondriale & Immunitaire, CNRS, UMR 6101, F-87025 Limoges, France
[2] Fac Sci, Inst Biotechnol, F-87060 Limoges, France
[3] Inst Bergonie, F-33076 Bordeaux, France
关键词
doxorubicin; lung resistance protein; multidrug resistance-associated protein; P-glycoprotein;
D O I
10.1097/00001813-200103000-00010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous studies have reported that P-glycoprotein (P-gp), a transmembrane efflux pump involved in multidrug resistance (MDR), was overexpressed in the doxorubicin (Dox)-resistant human erythroleukemia cell line K562. Nevertheless, several results suggested that P-gp was not the only mechanism involved in these resistant cells. Sequential co-expression of other Mon-associated proteins was sometimes reported, as MDR-associated protein (MRP) and lung resistance protein (LRP), in different MDR cell lines. Thus, mRNA expression and stability of P-gp, MRP and LRP were analyzed, while their corresponding protein levels were quantified in correlation with functional assay, in the K562 cell line and two Dox-resistant variants (K562/R). Their P-gp content was in accordance with their degree of resistance, but not as much in the level of mRNA expression, suggesting a posttranscriptional regulation. On the other hand, MRP could play a minor role in Mon because of an unchanged expression in K562/R sublines. A surprising progressive disappearance of LRP in both resistant cells suggested that the original mechanism of drug redistribution may be operative, involving a negative role for LRP. [(C) 2001 Lippincott Williams & Wilkins].
引用
收藏
页码:247 / 258
页数:12
相关论文
共 37 条
[1]   ISOLATION AND GENETIC-CHARACTERIZATION OF HUMAN KB-CELL LINES RESISTANT TO MULTIPLE-DRUGS [J].
AKIYAMA, SI ;
FOJO, A ;
HANOVER, JA ;
PASTAN, I ;
GOTTESMAN, MM .
SOMATIC CELL AND MOLECULAR GENETICS, 1985, 11 (02) :117-126
[2]   DIFFERENTIAL-EFFECTS OF VERAPAMIL AND QUININE ON THE REVERSAL OF DOXORUBICIN RESISTANCE IN A HUMAN LEUKEMIA-CELL LINE [J].
BENNIS, S ;
ICHAS, F ;
ROBERT, J .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (03) :283-290
[3]  
CHUGANI DC, 1993, J CELL SCI, V106, P23
[4]   OVEREXPRESSION OF A TRANSPORTER GENE IN A MULTIDRUG-RESISTANT HUMAN LUNG-CANCER CELL-LINE [J].
COLE, SPC ;
BHARDWAJ, G ;
GERLACH, JH ;
MACKIE, JE ;
GRANT, CE ;
ALMQUIST, KC ;
STEWART, AJ ;
KURZ, EU ;
DUNCAN, AMV ;
DEELEY, RG .
SCIENCE, 1992, 258 (5088) :1650-1654
[5]  
DENISGAY M, 1995, ANTICANCER RES, V15, P121
[6]   RESISTANCE TO DOXORUBICIN IN TUMOR-CELLS INVITRO AND INVIVO AFTER PRETREATMENT WITH VERAPAMIL [J].
DONENKO, FV ;
EFFERTH, T ;
MATTERN, J ;
MOROZ, LV ;
VOLM, M .
CHEMOTHERAPY, 1991, 37 (01) :57-61
[7]   THE BIOCHEMISTRY OF P-GLYCOPROTEIN-MEDIATED MULTIDRUG RESISTANCE [J].
ENDICOTT, JA ;
LING, V .
ANNUAL REVIEW OF BIOCHEMISTRY, 1989, 58 :137-171
[8]  
FLENS MJ, 1994, CANCER RES, V54, P4557
[9]  
HABER M, 1989, CANCER RES, V49, P5281
[10]  
HERZOG CE, 1993, J BIOL CHEM, V268, P2946